BioNexus Gene Lab Corp
BGLCOther · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $7.4M | $9.5M | $9.8M | $10.9M | $13.4M | $11.4M |
| Operating income | −$3.0M | −$1.6M | −$2.6M | −$291,177 | $1.1M | $1.3M |
| Net income | −$3.0M | −$1.6M | −$2.6M | −$355,966 | $751,571 | $1.1M |
| Total assets | $9.3M | $10.4M | $11.4M | $8.7M | $9.6M | $10.1M |
| Total liabilities | $637,856 | $2.1M | $1.7M | $2.1M | $2.4M | $3.5M |
| Equity | $8.6M | $8.3M | $9.7M | $6.7M | $7.2M | $6.7M |
| EPS (diluted) | — | $-0.09 | $-0.17 | — | — | — |
| Shares out. | 2.4M | 18.0M | 17.7M | 171.2M | 171.2M | 102.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −39.9%
- Net margin
- −40.2%
- Return on equity
- −34.6%
- Return on assets
- −32.3%
- Return on capital (ROCE)
- −34.0%
- Liabilities / assets
- 6.9%
- Debt / equity
- 0.07×
- Book value / share
- $3.56
- Revenue growth (YoY)
- −21.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 13.26safe
- Accruals / assets
- −12.4%clean
- Beneish M-Score
- -3.31normal
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 4 warning● 3 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 31, 2026
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2025
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2025
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2024
- NT 10-Kmissed a reporting deadline ↗Mar 28, 2024
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 10,574 | 2.2 | +5.9% |
| Apr 30, 2026 | 9,982 | 2.1 | +0.1% |
| Apr 15, 2026 | 9,968 | 4.5 | -58.1% |
| Mar 31, 2026 | 23,800 | 3.7 | +4.7% |
| Mar 13, 2026 | 22,737 | 3.8 | -16.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosure · Other material eventMar 17, 2026
- Other material eventFeb 23, 2026
- Other material eventFeb 3, 2026
- Shareholder voteDec 30, 2025
- Other material eventDec 23, 2025
- Entered a material agreement · Unregistered equity sale · Regulation FD disclosureDec 2, 2025
- Entered a material agreement · Regulation FD disclosureNov 13, 2025
- Entered a material agreement · Unregistered equity sale · Regulation FD disclosureNov 12, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-QFORM 10-QMay 15, 2026
- 10-KFORM 10-KApr 14, 2026
- NT 10-KMar 31, 2026
- 8-KFORM 8-KMar 17, 2026
- 8-KFORM 8-KFeb 23, 2026
- 8-KFORM 8-KFeb 3, 2026
- 8-KFORM 8-KDec 30, 2025
- 8-KFORM 8-KDec 23, 2025
- DEF 14ADec 3, 2025
- 8-KFORM 8-KDec 2, 2025
- 10-QFORM 10-QNov 14, 2025
- PRE 14ANov 14, 2025
- 8-KFORM 8-KNov 13, 2025
- 8-KFORM 8-KNov 12, 2025
- S-3FORM S-3Nov 7, 2025
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.